Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027906 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
A Phase 1 study of Prevention of Rejection in Kidney Transplant, sponsored by Eledon Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 9
- Study locations
NCT05027906 is a Phase 1 study of Prevention of Rejection in Kidney Transplant that is actively recruiting participants, run by Eledon Pharmaceuticals. The registered enrollment target is 48 participants. The trial reports 9 study locations across 6 states.
The verdict
NCT05027906, a Phase 1 study of Prevention of Rejection in Kidney Transplant, is actively recruiting participants, sponsored by Eledon Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
Conditions Studied
Interventions
- DRUG AT-1501
Study Locations (9)
Other
- Fundação Oswaldo Ramos - Hospital do Rim - São Paulo
- Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital - Liverpool
- Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital - Oxford
British Columbia
- Providence Health Care - St. Paul's Hospital - Vancouver
- Vancouver General Hospital - Vancouver
Ohio
- University of Cincinnati - Cincinnati
New South Wales
- Royal Prince Alfred Hospital - Camperdown
South Australia
- Royal Adelaide Hospital - Adelaide
Quebec
- McGill University Health Care Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027906
The ClinicalTrials.gov registry entry for NCT05027906 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eledon Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prevention of Rejection in Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which AT-1501 is the first listed.
NCT05027906 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, British Columbia, Ohio.
Frequently Asked Questions
What is clinical trial NCT05027906 about?
NCT05027906 is a clinical study titled "Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant". This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
What is the current status of trial NCT05027906?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-02-18. Estimated completion is 2027-01.
What conditions does trial NCT05027906 study?
This clinical trial studies the following conditions: Prevention of Rejection in Kidney Transplant.
What interventions are being tested in trial NCT05027906?
The interventions under investigation include: AT-1501 (DRUG).
Who is sponsoring clinical trial NCT05027906?
This trial is sponsored by Eledon Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027906 being conducted?
This trial has 9 study locations across Ohio, New South Wales, South Australia, British Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.